
Search
Filter Results
Displaying 451–460 of 1079 results
-
Feb 24, 2022
Second Sight Agrees to Merger to Maintain Retinal and Cortical Prostheses Programs
Company has been unable to meet revenue goals for the Argus II®
-
Feb 23, 2022
The March 6th virtual event will raise awareness and fund research leading to treatments and cures for blinding retinal diseases.
-
Feb 15, 2022
ProQR’s Phase 2/3 Clinical Trial for LCA10 RNA Therapy Doesn’t Meet Endpoints
The emerging treatment had shown encouraging results in a Phase ½ clinical trial
-
Feb 8, 2022
AGTC Plans Further Clinical Development of Achromatopsia (CNGB3) Gene Therapy
Interim results for pediatric patients with CNGB3 mutations were encouraging
-
VISIONS 2022, the national conference of the Foundation Fighting Blindness, is a one-of-a-kind event in which individuals who are visually impaired, and their families, have the opportunity to hear about exciting advancements in blindness research.
-
VISIONS 2022, the national conference of the Foundation Fighting Blindness, is a one-of-a-kind event in which individuals who are visually impaired, and their families, have the opportunity to hear about exciting advancements in blindness research.
-
VISIONS 2022, the national conference of the Foundation Fighting Blindness, is a one-of-a-kind event in which individuals who are visually impaired, and their families, have the opportunity to hear about exciting advancements in blindness research.
-
VISIONS 2022, the national conference of the Foundation Fighting Blindness, is a one-of-a-kind event in which individuals who are visually impaired, and their families, have the opportunity to hear about exciting advancements in blindness research.
-
Feb 1, 2022
Genentech-Roche Receives FDA Approval for Vabysmo for Treatment of Wet AMD and DME
This new treatment can reduce the frequency of injections into the eye
-
Jan 28, 2022
Kriya Therapeutics Licenses Emerging Foundation-Funded Dry AMD Gene Therapy
The Foundation Fighting Blindness is funding Bärb Rohrer, PhD, Medical University of South Carolina, to evaluate safety and efficacy of the gene therapy in a large animal model